Zacks Research Has Bearish Forecast for Teleflex Q2 Earnings

Teleflex Incorporated (NYSE:TFX) – Zacks Research dropped their Q2 2025 earnings per share (EPS) estimates for Teleflex in a research report issued to clients and investors on Tuesday, June 24th. Zacks Research analyst R. Department now expects that the medical technology company will post earnings per share of $3.34 for the quarter, down from their previous forecast of $3.35. The consensus estimate for Teleflex’s current full-year earnings is $13.98 per share. Zacks Research also issued estimates for Teleflex’s Q3 2025 earnings at $3.36 EPS, Q4 2025 earnings at $3.72 EPS, FY2025 earnings at $13.33 EPS, Q3 2026 earnings at $3.78 EPS, Q4 2026 earnings at $3.51 EPS and FY2026 earnings at $13.74 EPS.

Several other brokerages have also commented on TFX. Citizens Jmp lowered Teleflex from an “outperform” rating to a “market perform” rating in a report on Thursday, February 27th. Truist Financial dropped their price objective on Teleflex from $140.00 to $137.00 and set a “hold” rating on the stock in a report on Monday, May 5th. Wells Fargo & Company lowered their price target on Teleflex from $146.00 to $137.00 and set an “equal weight” rating on the stock in a research note on Friday, May 2nd. Raymond James Financial lowered Teleflex from an “outperform” rating to a “market perform” rating in a research note on Friday, February 28th. Finally, Piper Sandler reaffirmed a “neutral” rating and issued a $140.00 price target (down from $255.00) on shares of Teleflex in a research note on Friday, February 28th. One investment analyst has rated the stock with a sell rating, eight have given a hold rating and three have assigned a buy rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Hold” and an average target price of $164.63.

Teleflex Stock Up 0.3%

Shares of TFX opened at $119.45 on Thursday. The company has a current ratio of 2.28, a quick ratio of 1.32 and a debt-to-equity ratio of 0.44. Teleflex has a 12 month low of $115.94 and a 12 month high of $249.91. The stock’s 50 day moving average is $124.61 and its two-hundred day moving average is $148.29. The firm has a market cap of $5.28 billion, a P/E ratio of 37.68, a PEG ratio of 1.87 and a beta of 1.10.

Teleflex (NYSE:TFX) last issued its quarterly earnings data on Thursday, May 1st. The medical technology company reported $2.91 EPS for the quarter, beating the consensus estimate of $2.88 by $0.03. Teleflex had a return on equity of 14.73% and a net margin of 4.96%. The company had revenue of $700.67 million for the quarter, compared to analyst estimates of $699.37 million. During the same period last year, the company earned $3.21 earnings per share. Teleflex’s quarterly revenue was down 5.0% compared to the same quarter last year.

Hedge Funds Weigh In On Teleflex

Institutional investors have recently added to or reduced their stakes in the stock. T. Rowe Price Investment Management Inc. raised its position in Teleflex by 0.7% in the first quarter. T. Rowe Price Investment Management Inc. now owns 6,216,763 shares of the medical technology company’s stock valued at $859,095,000 after purchasing an additional 43,642 shares during the period. Geode Capital Management LLC increased its holdings in Teleflex by 0.7% during the 4th quarter. Geode Capital Management LLC now owns 1,138,867 shares of the medical technology company’s stock worth $202,161,000 after purchasing an additional 8,307 shares during the period. Cooke & Bieler LP increased its holdings in Teleflex by 22.1% during the 4th quarter. Cooke & Bieler LP now owns 1,078,557 shares of the medical technology company’s stock worth $191,962,000 after purchasing an additional 195,150 shares during the period. Invesco Ltd. boosted its position in shares of Teleflex by 48.1% during the 4th quarter. Invesco Ltd. now owns 1,068,593 shares of the medical technology company’s stock worth $190,188,000 after acquiring an additional 347,003 shares in the last quarter. Finally, Dimensional Fund Advisors LP boosted its position in shares of Teleflex by 69.5% during the 1st quarter. Dimensional Fund Advisors LP now owns 867,864 shares of the medical technology company’s stock worth $119,927,000 after acquiring an additional 355,720 shares in the last quarter. Hedge funds and other institutional investors own 95.62% of the company’s stock.

Teleflex Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Monday, June 16th. Investors of record on Tuesday, May 20th were given a dividend of $0.34 per share. The ex-dividend date of this dividend was Tuesday, May 20th. This represents a $1.36 dividend on an annualized basis and a yield of 1.14%. Teleflex’s payout ratio is 42.90%.

About Teleflex

Teleflex Incorporated designs, develops, manufactures, and supplies single-use medical devices for common diagnostic and therapeutic procedures in critical care and surgical applications worldwide. The company provides vascular access products that comprise Arrow branded catheters, catheter navigation and tip positioning systems, and intraosseous access systems for the administration of intravenous therapies, the measurement of blood pressure, and the withdrawal of blood samples through a single puncture site.